Cochrane · systematic review · CD004956
Bisphosphonates for Paget's disease of bone in adults
Corral‐Gudino, L, Tan, AJH, del Pino‐Montes, J, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
MusculoskeletalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 7 · 50%Very low 3 · 21.4%Low 3 · 21.4%Moderate 1 · 7.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Bisphosphonates versus placebo for Paget's disease of bone
Population: Paget's disease of bone
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants with change in bone pain (disappearance of pain)¹assessed on VAS Bisphosphonates vs placebo | RR 3.42 [1.31, 8.9] | 2 studies · 205 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Number of participants who experienced radiologically‐confirmed fractures Bisphosphonates vs placebo | RR 0.89 [0.18, 4.31] | 4 studies · 356 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Number of participants who needed orthopaedic surgery (not measured) Bisphosphonates vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Number of participants with change in quality of life measures (not measured) Bisphosphonates vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Number of participants with change in hearing thresholds (not measured) Bisphosphonates vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Number of participants who experienced side effects related to use of bisphosphonates Bisphosphonates vs placebo | RR 1.32 [0.91, 1.92] | 6 studies · 678 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Number of participants who withdrew due to adverse events Bisphosphonates vs placebo | RR 1.01 [0.41, 2.52] | 6 studies · 517 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Zoledronate versus pamidronate or risedronate for Paget's disease of bone
Population: Paget's disease of bone
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants with change in bone pain¹ assessed on VAS. Zoledronate vs pamidronate or risedronate | RR 1.31 [1.15, 1.51] | 2 studies · 436 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Number of participants who experienced fractures (not measured) Zoledronate vs pamidronate or risedronate | no estimate extracted | 0 studies · 0 participants | Ungraded |
Number of participants who needed orthopaedic surgery (not measured) Zoledronate vs pamidronate or risedronate | no estimate extracted | 0 studies · 0 participants | Ungraded |
Number of participants with change in quality of life measures (not measured) Zoledronate vs pamidronate or risedronate | no estimate extracted | 0 studies · 0 participants | Ungraded |
Number of participants with change in hearing thresholds (not measured) Zoledronate vs pamidronate or risedronate | no estimate extracted | 0 studies · 0 participants | Ungraded |
Number of participants who experienced side effects related to use of bisphosphonates. Zoledronate vs pamidronate or risedronate | RR 1.05 [0.95, 1.16] | 2 studies · 437 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Number of participants who withdrew due to adverse events (withdrawals) Zoledronate vs pamidronate or risedronate | RR 2.04 [0.43, 9.59] | 2 studies · 437 participants | Very low Downgraded: risk of bias, imprecision, indirectness |